Bio Green Med Solution (BGMS) AI Stock Analysis

• Market Cap: $6.91M
• Dividend Yield: 10.27%
• Average Volume (3M): 473.94K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.59
• Revenue Growth: 9.46%
• EPS Growth: 96.85%
• Country: US
• Employees: 12
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Pharmaceuticals
• EPS (TTM): -1.31
• Shares Outstanding: 4,900,142
• 10 Day Avg. Volume: 1,252,948
• 30 Day Avg. Volume: 473,939
• PEG Ratio: <0.01
• Price to Book (P/B): -0.06
• Price to Sales (P/S): 3.12
• P/FCF Ratio: -0.02
• Enterprise Value/Market Cap: 0.52
• Enterprise Value/Revenue: 44.27
• Enterprise Value/Gross Profit: 224.11
• Enterprise Value/Ebitda: -0.39
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: $1.50 ▲(3.45% Upside)

The score is primarily held down by persistent losses and substantial cash burn relative to a very small revenue base, despite an improved and low-debt balance sheet. Technicals further weigh on the outlook as the stock remains below major moving averages with negative MACD. Valuation is mixed: a high dividend yield is supportive, but negative earnings and weak cash generation limit its impact.

Bio Green Med Solution Business Overview & Revenue Model

Company Description

A diversified company operating in both the fire protection and biopharmaceutical industries. It expanded its portfolio by acquiring Fitters Sdn. Bhd., a Malaysian fire protection products and services group. Focuses on advancing opportunities in biopharmaceutical research and fire safety solutions to create sustainable long-term shareholder value.

How the Company Makes Money

Cyclacel Pharmaceuticals generates revenue primarily through the development and commercialization of its proprietary cancer therapies. The company’s revenue model is centered around licensing agreements, collaborations, and strategic partnerships with other pharmaceutical companies. These agreements often include upfront payments, milestone payments, and royalties on sales of successfully developed products. Additionally, Cyclacel may receive funding from government grants and research collaborations, which support their clinical trials and research initiatives. As a clinical-stage company, significant revenue generation typically occurs post-commercialization of their drug candidates.

Bio Green Med Solution Financial Statement Overview

Summary

Cyclacel Pharmaceuticals is facing significant financial challenges, characterized by operational losses, negative cash flows, and a weak balance sheet. The company needs to improve operational efficiency and stabilize its financial position to enhance investor confidence.

Income Statement

Cyclacel Pharmaceuticals has exhibited a volatile revenue pattern with recent growth from a low base. The gross profit margin is 100% due to low revenue, while the net profit margin remains negative due to significant losses. EBIT and EBITDA margins are also negative, reflecting operational inefficiencies.

Balance Sheet

The balance sheet indicates high leverage with negative stockholders' equity, suggesting financial instability. The equity ratio is negative, and the company has no debt, which is positive, but high liabilities limit flexibility. Return on equity is not meaningful due to negative equity.

Cash Flow

The company has consistently reported negative free cash flow, indicating challenges in generating cash from operations. The operating cash flow to net income ratio is negative, highlighting inefficiencies in cash conversion.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	81.00K	43.00K	420.00K	0.00	0.00	0.00
Gross Profit	16.00K	43.00K	420.00K	0.00	0.00	-20.00K
EBITDA	-9.23M	-12.00M	-25.42M	-27.62M	-22.35M	-9.66M
Net Income	-5.44M	-11.21M	-22.55M	-21.20M	-18.46M	-8.45M
Balance Sheet
Total Assets	8.16M	4.09M	8.80M	28.05M	43.14M	36.80M
Cash, Cash Equivalents and Short-Term Investments	3.84M	3.14M	3.38M	18.34M	36.56M	33.41M
Total Debt	5.00K	0.00	37.00K	106.00K	30.00K	1.06M
Total Liabilities	1.06M	6.27M	8.20M	7.62M	5.44M	3.54M
Stockholders Equity	7.10M	-2.17M	607.00K	20.43M	37.69M	33.26M
Cash Flow
Free Cash Flow	-6.09M	-7.99M	-16.12M	-20.83M	-18.57M	-8.03M
Operating Cash Flow	-6.09M	-7.99M	-16.11M	-20.83M	-18.54M	-7.93M
Investing Cash Flow	0.00	0.00	-6.00K	-7.00K	-27.00K	-96.00K
Financing Cash Flow	7.14M	7.82M	848.00K	3.00M	21.74M	29.50M

Bio Green Med Solution Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.45
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BGMS, the sentiment is Negative. The current price of 1.45 is below the 20-day moving average (MA) of 1.50, below the 50-day MA of 1.55, and below the 200-day MA of 17.76, indicating a bearish trend. The MACD of -0.09 indicates Negative momentum. The RSI at 43.47 is Neutral, neither overbought nor oversold. The STOCH value of 45.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BGMS.

Bio Green Med Solution Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NEUP	52 Neutral	$20.54M	-0.16	-59.91%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
RNTX	48 Neutral	$32.86M	-0.47	-83.28%	―	―	15.35%
BGMS	44 Neutral	$6.91M	-0.02	-226.28%	10.27%	9.46%	96.85%
BJDX	44 Neutral	$1.19M	-0.02	-126.20%	―	―	97.70%
SLRX	42 Neutral	$4.16M	-0.02	-139.55%	―	―	68.08%
BDRX	41 Neutral	$1.52M	-0.04	-60.37%	―	-100.00%	86.75%

Bio Green Med Solution Corporate Events

Bio Green Med Solution Reports Q3 Financial Results

On November 13, 2025, Bio Green Med Solution reported its third-quarter financial results, highlighting several strategic moves to strengthen its market position. Key developments included a reverse stock split in July, a warrant exchange agreement in September, and the acquisition of Fitters Sdn. Bhd., which became a wholly-owned subsidiary. The company also sold assets related to Plogosertib, a cancer treatment, and declared a cash dividend on its preferred stock. Financially, the company reported a net loss of $1.0 million for the quarter, with cash reserves expected to support operations into early 2026.

Bio Green Med Solution’s Warrant Exchange Agreement

On November 5, 2025, Bio Green Med Solution, Inc. entered into a Warrant Exchange Agreement with accredited investors to exchange existing warrants for 1,402,605 shares of common stock. This move, leveraging an exemption under the Securities Act of 1933, is poised to impact the company’s financial structure and stakeholder equity without requiring registration.

Bio Green Med Solution Finalizes Asset Sale to Tethra

On October 6, 2025, Bio Green Med Solution, Inc. finalized an Asset Purchase Agreement with Tethra Biosciences Inc. to sell certain assets, including all patent rights related to Plogosertib, a PLK 1 inhibitor, for $300,000 with a potential milestone payment of $170,000. This transaction marks a significant shift in Bio Green Med Solution’s operations, potentially impacting its market positioning and stakeholders by transferring key intellectual property to Tethra Biosciences.

Bio Green Med Solution Announces Quarterly Cash Dividend

On October 7, 2025, Bio Green Med Solution, Inc. announced a quarterly cash dividend of $0.15 per share on its 6% Convertible Exchangeable Preferred Stock. The dividend will be paid on November 1, 2025, to stockholders of record as of October 20, 2025.